| (Values in U.S. Thousands) | Dec, 2023 | Jun, 2023 | Dec, 2022 | Jun, 2022 | Mar, 2022 |
| Sales | 11,920 | 11,590 | 48,280 | 35,610 | 62,500 |
| Sales Growth | +2.85% | -75.99% | +35.58% | -43.02% | unch |
| Net Income | -11,010 | -7,270 | -14,340 | -25,520 | -9,680 |
| Net Income Growth | -51.44% | +49.30% | +43.81% | -163.64% | unch |
Centogene N.V. (CNTGF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Centogene is a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies. The Company's goal is to bring rationality to treatment decisions and to accelerate the development of new orphan drugs by using their knowledge of the global rare disease market, including epidemiological and clinical data and innovative biomarkers.
Fiscal Year End Date: 12/31